Consolidated subsidiary Syncs Healthcare plans to conclude an outsourcing agreement with CM Plus Inc. in April 2026 to obtain PMDA approval for botulinum toxin formulation.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6574","jir_company_name":"CONVANO Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/6574-20260327-01.pdf","jir_short_summary":"Consolidated subsidiary Syncs Healthcare plans to conclude an outsourcing agreement with CM Plus Inc. in April 2026 to obtain PMDA approval for botulinum toxin formulation.","jir_summary":"### Overview of Outsourcing Agreement\nCONVANO Inc.'s consolidated subsidiary, Syncs Healthcare Inc., aims to obtain PMDA approval for botulinum toxin formulation domestically in Japan and plans to conclude an outsourcing agreement with CM Plus Inc., a company specialized in pharmaceutical regulatory application support. CM Plus will provide comprehensive support including regulatory strategy assessment, quality (CMC) evaluation, clinical package assessment, GMP, supply, and legal risk evaluations to enhance the accuracy and expedite the preparation of the approval application.\n\n### Future Outlook and Impact on Business Performance\nThe contract is scheduled for conclusion in April 2026, and the impact on FY2026 results is expected to be minimal. The FY2027 business plan does not include sales from this formulation, but certain costs are already factored in. From FY2028 onward, progress in approval acquisition and market launch plans could significantly impact performance, but the amount of impact is currently unknown and under review. If approval is granted, expanded sales through existing sales channels targeting aesthetic medical clinics and continuous revenue generation are expected.","jir_financial_highlights":"Impact of this contract on FY2026 results: Minimal (Unknown)\nConsolidated FY2027 revenue forecast: 23,700 million yen (Unknown)\nConsolidated FY2027 operating income forecast: 9,500 million yen (Unknown)","jir_category":"","jir_hashtags":"#CONVANOInc, #business_update, #JapaneseStocks","jir_key_figures":"Impact on FY2026 results: Minimal\nFY2027 revenue forecast: 23,700 million yen (sales of botulinum toxin formulation not included)\nFY2027 operating income forecast: 9,500 million yen","jir_meta_title":"CONVANO Inc. Concludes Outsourcing Agreement for PMDA Approval of Botulinum Toxin Formulation","jir_meta_description":"Consolidated subsidiary Syncs Healthcare of CONVANO Inc. plans to conclude an outsourcing agreement with CM Plus Inc. to obtain PMDA approval for a botulinum toxin formulation. Impact on FY2026 results is expected to be minimal.","jir_og_title":"CONVANO Inc. Concludes Outsourcing Agreement for Approval of Botulinum Toxin Formulation","jir_og_description":"Consolidated subsidiary establishes support system to obtain PMDA approval. Impact on FY2026 results is expected to be minimal.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17006,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-37397","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n